These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 21426218

  • 1. Using the medical food flavocoxid [corrected] in managing osteoarthritis.
    Gottlieb D, Kuritzky L.
    J Pain Palliat Care Pharmacother; 2011; 25(1):49-54. PubMed ID: 21426218
    [Abstract] [Full Text] [Related]

  • 2. Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study.
    Levy RM, Saikovsky R, Shmidt E, Khokhlov A, Burnett BP.
    Nutr Res; 2009 May; 29(5):298-304. PubMed ID: 19555810
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee.
    Levy RM, Khokhlov A, Kopenkin S, Bart B, Ermolova T, Kantemirova R, Mazurov V, Bell M, Caldron P, Pillai L, Burnett BP.
    Adv Ther; 2010 Oct; 27(10):731-42. PubMed ID: 20845002
    [Abstract] [Full Text] [Related]

  • 4. GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin.
    Pillai L, Burnett BP, Levy RM, GOAL Study Cooperative Group.
    Curr Med Res Opin; 2010 May; 26(5):1055-63. PubMed ID: 20225990
    [Abstract] [Full Text] [Related]

  • 5. Cost analysis of flavocoxid compared to naproxen for management of mild to moderate OA.
    Walton SM, Schumock GT, McLain DA.
    Curr Med Res Opin; 2010 Sep; 26(9):2253-61. PubMed ID: 20690891
    [Abstract] [Full Text] [Related]

  • 6. Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies.
    Pillai L, Levy RM, Yimam M, Zhao Y, Jia Q, Burnett BP.
    Adv Ther; 2010 Jun; 27(6):400-11. PubMed ID: 20556559
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant.
    Burnett BP, Bitto A, Altavilla D, Squadrito F, Levy RM, Pillai L.
    Mediators Inflamm; 2011 Jun; 2011():385780. PubMed ID: 21765617
    [Abstract] [Full Text] [Related]

  • 9. 5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity.
    Burnett BP, Levy RM.
    Adv Ther; 2012 Feb; 29(2):79-98. PubMed ID: 22351432
    [Abstract] [Full Text] [Related]

  • 10. Flavocoxid, a nutraceutical approach to blunt inflammatory conditions.
    Bitto A, Squadrito F, Irrera N, Pizzino G, Pallio G, Mecchio A, Galfo F, Altavilla D.
    Mediators Inflamm; 2014 Feb; 2014():790851. PubMed ID: 25242871
    [Abstract] [Full Text] [Related]

  • 11. Topical therapy for osteoarthritis: clinical and pharmacologic perspectives.
    Altman R, Barkin RL.
    Postgrad Med; 2009 Mar; 121(2):139-47. PubMed ID: 19332972
    [Abstract] [Full Text] [Related]

  • 12. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study.
    Mastbergen SC, Jansen NW, Bijlsma JW, Lafeber FP.
    Arthritis Res Ther; 2006 Mar; 8(1):R2. PubMed ID: 16356188
    [Abstract] [Full Text] [Related]

  • 13. Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
    Pallio G, Bitto A, Pizzino G, Galfo F, Irrera N, Minutoli L, Arcoraci V, Squadrito G, Macrì A, Squadrito F, Altavilla D.
    Eur J Pharmacol; 2016 Oct 15; 789():152-162. PubMed ID: 27450484
    [Abstract] [Full Text] [Related]

  • 14. Two-pronged approach to anti-inflammatory therapy through the modulation of the arachidonic acid cascade.
    Sala A, Proschak E, Steinhilber D, Rovati GE.
    Biochem Pharmacol; 2018 Dec 15; 158():161-173. PubMed ID: 30315753
    [Abstract] [Full Text] [Related]

  • 15. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.
    J Med Assoc Thai; 2009 Dec 15; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [Abstract] [Full Text] [Related]

  • 16. Managing osteoarthritic knee pain.
    Barron MC, Rubin BR.
    J Am Osteopath Assoc; 2007 Nov 15; 107(10 Suppl 6):ES21-7. PubMed ID: 17986674
    [Abstract] [Full Text] [Related]

  • 17. Comparative safety of flavocoxid vs prescription NSAIDs among osteoarthritis patients.
    Curtis JR, Owensby JK, Xie F.
    Osteoarthritis Cartilage; 2020 Jul 15; 28(7):917-923. PubMed ID: 32305527
    [Abstract] [Full Text] [Related]

  • 18. Should nonsteroidal anti-inflammatory drugs be used to treat osteoarthritis?
    Brandt KD.
    Rheum Dis Clin North Am; 1993 Feb 15; 19(1):29-44. PubMed ID: 8356260
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Differential inhibition of murine prostaglandin synthase-1 and -2 by nonsteroidal anti-inflammatory drugs using exogenous and endogenous sources of arachidonic acid.
    Chulada PC, Langenbach R.
    J Pharmacol Exp Ther; 1997 Feb 15; 280(2):606-13. PubMed ID: 9023270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.